MXCT fundamentals
MaxCyte, Inc. revenue breakdown overview
MaxCyte, Inc. revenue for the last year amounted to 38.63 M USD, the most of which — 14.01 M USD — came from its highest performing source at the moment, PA and Consumable Revenue. The greatest contribution to the revenue figure was made by United States — last year it brought MaxCyte, Inc. 25.77 M USD, and the year before that — 41.29 M USD.
By source
2017
2018
2019
2020
2021
2022
2023
2024
0.00
12.00 M
24.00 M
36.00 M
48.00 M
PA and Consumable Revenue
License
Instrument
SPL Program-related
Other
Cell Therapy
Program-related
Drug Discovery
Leased Elements
Currency: USD
2017
2018
2019
2020
2021
2022
2023
2024
PA and Consumable Revenue
—
—
—
—
14.01 M
License
—
—
—
—
10.30 M
Instrument
—
—
—
—
7.08 M
SPL Program-related
—
—
—
—
6.12 M
Other
601.30 K
—
—
—
1.13 M
Cell Therapy
14.85 M
22.98 M
30.55 M
22.83 M
—
Program-related
—
2.52 M
4.62 M
11.46 M
—
Drug Discovery
—
8.39 M
9.10 M
6.99 M
—
Leased Elements
10.72 M
—
—
—
—
By country
2017
2018
2019
2020
2021
2022
2023
2024
0.00
12.00 M
24.00 M
36.00 M
48.00 M
United States
Non-United States
Currency: USD
2017
2018
2019
2020
2021
2022
2023
2024
United States
26.17 M
33.89 M
44.26 M
41.29 M
25.77 M
Non-United States
—
—
—
—
12.86 M